Bristol-Myers Squibb Co (BMY) : Headinvest reduced its stake in Bristol-Myers Squibb Co by 2.11% during the most recent quarter end. The investment management company now holds a total of 12,400 shares of Bristol-Myers Squibb Co which is valued at $876,432 after selling 267 shares in Bristol-Myers Squibb Co , the firm said in a disclosure report filed with the SEC on Apr 21, 2016.Bristol-Myers Squibb Co makes up approximately 0.34% of Headinvest’s portfolio.
Bristol-Myers Squibb Co closed down -0.63 points or -0.89% at $70.23 with 75,72,214 shares getting traded on Wednesday. Post opening the session at $70.86, the shares hit an intraday low of $68.615 and an intraday high of $71 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
Other Hedge Funds, Including , Everence Capital Management Inc boosted its stake in BMY in the latest quarter, The investment management firm added 3,480 additional shares and now holds a total of 38,127 shares of Bristol-Myers Squibb Co which is valued at $2,694,816. Bristol-Myers Squibb Co makes up approx 0.82% of Everence Capital Management Inc’s portfolio. Integrated Investment Consultants added BMY to its portfolio by purchasing 4,000 company shares during the most recent quarter which is valued at $272,200. Bristol-Myers Squibb Co makes up approx 0.15% of Integrated Investment Consultants’s portfolio.Blue Bell Private Wealth Management reduced its stake in BMY by selling 92 shares or 23.47% in the most recent quarter. The Hedge Fund company now holds 300 shares of BMY which is valued at $20,415. Bristol-Myers Squibb Co makes up approx 0.01% of Blue Bell Private Wealth Management’s portfolio.Central Trust Co boosted its stake in BMY in the latest quarter, The investment management firm added 949 additional shares and now holds a total of 180,734 shares of Bristol-Myers Squibb Co which is valued at $12,298,949. Bristol-Myers Squibb Co makes up approx 0.96% of Central Trust Co’s portfolio.Eqis Capital Management boosted its stake in BMY in the latest quarter, The investment management firm added 1,705 additional shares and now holds a total of 18,420 shares of Bristol-Myers Squibb Co which is valued at $1,215,352. Bristol-Myers Squibb Co makes up approx 0.09% of Eqis Capital Management’s portfolio.
On the company’s financial health, Bristol-Myers Squibb Co reported $0.38 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Jan 28, 2016. Analyst had a consensus of $0.28. The company had revenue of $4287.00 million for the quarter, compared to analysts expectations of $4154.19 million. The company’s revenue was up .7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.46 EPS.
Many Wall Street Analysts have commented on Bristol-Myers Squibb Co. Societe Generale Initiated Bristol-Myers Squibb Co on Apr 6, 2016 to “Sell”, Price Target of the shares are set at $48.
Bristol-Myers Squibb Company (BMS) is engaged in the discovery development licensing manufacturing marketing distribution and sale of biopharmaceutical products across the world. The Company’s products are sold to wholesalers retail pharmacies hospitals government entities and the medical profession. The Company manufactures its products in the United States Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers such as doctors nurse practitioners physician assistants pharmacists technologists hospitals Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print radio television and digital advertising and promotion. In addition the Company holds rights to F001287 which is a preclinical small-molecule IDO1-inhibitor.